376 related articles for article (PubMed ID: 29700872)
1. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function.
Abdel-Gadir A; Schneider L; Casini A; Charbonnier LM; Little SV; Harrington T; Umetsu DT; Rachid R; Chatila TA
Clin Exp Allergy; 2018 Jul; 48(7):825-836. PubMed ID: 29700872
[TBL] [Abstract][Full Text] [Related]
2. Successful Milk Oral Immunotherapy Promotes Generation of Casein-Specific CD137
Zhang Y; Li L; Genest G; Zhao W; Ke D; Bartolucci S; Pavey N; Al-Aubodah TA; Lejtenyi D; Torabi B; Ben-Shoshan M; Mazer B; Piccirillo CA
Front Immunol; 2021; 12():705615. PubMed ID: 34887847
[TBL] [Abstract][Full Text] [Related]
3. A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut-allergic adolescents.
van der Heiden M; Nopp A; Brandström J; Carvalho-Queiroz C; Nilsson C; Sverremark-Ekström E
Scand J Immunol; 2021 Apr; 93(4):e13005. PubMed ID: 33244763
[TBL] [Abstract][Full Text] [Related]
4. Analysis of cytokine production by peanut-reactive T cells identifies residual Th2 effectors in highly allergic children who received peanut oral immunotherapy.
Wisniewski JA; Commins SP; Agrawal R; Hulse KE; Yu MD; Cronin J; Heymann PW; Pomes A; Platts-Mills TA; Workman L; Woodfolk JA
Clin Exp Allergy; 2015 Jul; 45(7):1201-13. PubMed ID: 25823600
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy.
Frischmeyer-Guerrerio PA; Masilamani M; Gu W; Brittain E; Wood R; Kim J; Nadeau K; Jarvinen KM; Grishin A; Lindblad R; Sampson HA
J Allergy Clin Immunol; 2017 Oct; 140(4):1043-1053.e8. PubMed ID: 28414061
[TBL] [Abstract][Full Text] [Related]
6. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).
Syed A; Garcia MA; Lyu SC; Bucayu R; Kohli A; Ishida S; Berglund JP; Tsai M; Maecker H; O'Riordan G; Galli SJ; Nadeau KC
J Allergy Clin Immunol; 2014 Feb; 133(2):500-10. PubMed ID: 24636474
[TBL] [Abstract][Full Text] [Related]
7. High- and low-dose oral immunotherapy similarly suppress pro-allergic cytokines and basophil activation in young children.
Kulis M; Yue X; Guo R; Zhang H; Orgel K; Ye P; Li Q; Liu Y; Kim E; Burks AW; Vickery BP
Clin Exp Allergy; 2019 Feb; 49(2):180-189. PubMed ID: 30126028
[TBL] [Abstract][Full Text] [Related]
8. Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab.
Manohar M; Dunham D; Gupta S; Yan Z; Zhang W; Minnicozzi S; Kirkey M; Bunning B; Roy Chowdhury R; Galli SJ; Boyd SD; Kost LE; Chinthrajah RS; Desai M; Oettgen HC; Maecker HT; Yu W; DeKruyff RH; Andorf S; Nadeau KC
Allergy; 2021 Sep; 76(9):2809-2826. PubMed ID: 33782956
[TBL] [Abstract][Full Text] [Related]
9. Identification and analysis of peanut-specific effector T and regulatory T cells in children allergic and tolerant to peanut.
Weissler KA; Rasooly M; DiMaggio T; Bolan H; Cantave D; Martino D; Neeland MR; Tang MLK; Dang TD; Allen KJ; Frischmeyer-Guerrerio PA
J Allergy Clin Immunol; 2018 May; 141(5):1699-1710.e7. PubMed ID: 29454004
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab.
Yee CSK; Albuhairi S; Noh E; El-Khoury K; Rezaei S; Abdel-Gadir A; Umetsu DT; Burke-Roberts E; LeBovidge J; Schneider L; Rachid R
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):451-461.e7. PubMed ID: 30267889
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of oral immunotherapy.
Barshow SM; Kulis MD; Burks AW; Kim EH
Clin Exp Allergy; 2021 Apr; 51(4):527-535. PubMed ID: 33417257
[TBL] [Abstract][Full Text] [Related]
12. Current Trend in Immunotherapy for Peanut Allergy.
Joo Chan C; Richardo T; Lim RLH
Int Rev Immunol; 2018; 37(6):279-290. PubMed ID: 30638084
[TBL] [Abstract][Full Text] [Related]
13. Suppression of the immunologic response to peanut during immunotherapy is often transient.
Gorelik M; Narisety SD; Guerrerio AL; Chichester KL; Keet CA; Bieneman AP; Hamilton RG; Wood RA; Schroeder JT; Frischmeyer-Guerrerio PA
J Allergy Clin Immunol; 2015 May; 135(5):1283-92. PubMed ID: 25542883
[TBL] [Abstract][Full Text] [Related]
14. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents.
Brandström J; Vetander M; Sundqvist AC; Lilja G; Johansson SGO; Melén E; Sverremark-Ekström E; Nopp A; Nilsson C
Clin Exp Allergy; 2019 Oct; 49(10):1328-1341. PubMed ID: 31329313
[TBL] [Abstract][Full Text] [Related]
15. Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut.
Dioszeghy V; Mondoulet L; Puteaux E; Dhelft V; Ligouis M; Plaquet C; Dupont C; Benhamou PH
Cell Mol Immunol; 2017 Sep; 14(9):770-782. PubMed ID: 27063469
[TBL] [Abstract][Full Text] [Related]
16. Food allergen (peanut)-specific TH2 clones generated from the peripheral blood of a patient with peanut allergy.
de Jong EC; Spanhaak S; Martens BP; Kapsenberg ML; Penninks AH; Wierenga EA
J Allergy Clin Immunol; 1996 Jul; 98(1):73-81. PubMed ID: 8765820
[TBL] [Abstract][Full Text] [Related]
17. Food-allergic infants have impaired regulatory T-cell responses following in vivo allergen exposure.
Dang TD; Allen KJ; J Martino D; Koplin JJ; Licciardi PV; Tang ML
Pediatr Allergy Immunol; 2016 Feb; 27(1):35-43. PubMed ID: 26456457
[TBL] [Abstract][Full Text] [Related]
18. Peanut-specific type 1 regulatory T cells induced in vitro from allergic subjects are functionally impaired.
Pellerin L; Jenks JA; Chinthrajah S; Dominguez T; Block W; Zhou X; Noshirvan A; Gregori S; Roncarolo MG; Nadeau KC; Bacchetta R
J Allergy Clin Immunol; 2018 Jan; 141(1):202-213.e8. PubMed ID: 28689791
[TBL] [Abstract][Full Text] [Related]
19. Combining anti-IgE with oral immunotherapy.
Lin C; Lee IT; Sampath V; Dinakar C; DeKruyff RH; Schneider LC; Nadeau KC
Pediatr Allergy Immunol; 2017 Nov; 28(7):619-627. PubMed ID: 28782296
[TBL] [Abstract][Full Text] [Related]
20. Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children.
Thyagarajan A; Jones SM; Calatroni A; Pons L; Kulis M; Woo CS; Kamalakannan M; Vickery BP; Scurlock AM; Wesley Burks A; Shreffler WG
Clin Exp Allergy; 2012 Aug; 42(8):1197-205. PubMed ID: 22805467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
